Medical specialists from Spain tagged as investigators in clinical trials studying Polycythemia Vera

Total 11 results

Alberto Álvarez, MD
Seen in:
- Barcelona, Hospital Clinic de Barcelona
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Ángeles Fernández Rodríguez
Seen in:
- Asturias, Oviedo, Hospital Universitario Central de Asturias
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Anna Angona Figueras
Seen in:
- Girona, ICO Girona - Hospital Universitari de Girona
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Jesús María Hernández Rivas
Seen in:
- Salamanca, Hospital Universitario de Salamanc
- Salamanca, Hospital Universitario de Salamanca
Trials:
- NCT03589326 (Principal Investigator)
- NCT04603495 (Principal Investigator)
Conditions:
Juan Antonio Vera Goñi
Seen in:
- Sevilla, Hospital Virgen Macarena
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Juan Carlos Hernández Boluda
Seen in:
- Valencia, Hospital Clinico Universitario
- Valencia, Hospital Clinico Universitario de Valencia
Trials:
- NCT04603495 (Principal Investigator)
- NCT04385160 (Principal Investigator)
Conditions:
Ma Angeles Goni Herranz
Seen in:
- Pamplona, Complejo Hospitalario de Navarra
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Maria Laura Fox
Seen in:
- Barcelona, Vall d'Hebron Institute of Oncology
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Maria Teresa Gomez Casares, MD
Seen in:
- Las Palmas de Gran Canaria, Hospital Universitario de Gran Canaria Dr. Negrin
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Raquel Mata Serna
Seen in:
- Madrid, Hospital Universitario Fundación Jiménez Díaz
Trials:
- NCT04603495 (Principal Investigator)
Conditions:
Victor Higuero Saavedra, MD
Seen in:
- Caceres, Hospital San Pedro de Alcántara
Trials:
- NCT04603495 (Principal Investigator)
Conditions:

Clinical Trials on Polycythemia Vera

PharmaEssentia Japan K.K.

Recruiting

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Polycythemia Vera (PV)

Japan
Novartis Pharmaceuticals

Completed

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

Polycythemia Vera (PV)

United States
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; Incyte Corporation

Recruiting

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Myelofibrosis Due to and Following Polycythemia Vera

United States
PharmaEssentia Japan K.K.

Recruiting

A Study to Evaluate P1101 in Japanese PV Patients

Polycythemia Vera (PV)

Japan
PharmaEssentia Japan K.K.

Completed

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Polycythemia Vera (PV)

Japan
Northwestern University
National Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma Society

Withdrawn

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

United States
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

Phlebotomy Dependent Polycythemia Vera

United States, Canada, Hungary, United Kingdom, Australia, Poland
Novartis Pharmaceuticals

Terminated

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera | Post-Essential Thrombocytopenia

United States
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Austria, Spain, Australia, Canada, Japan, United States, Korea, Republic of, Romania, Israel, Italy, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Colombia, Argentina, Chile and more
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom

Medical specialists from Spain tagged as investigators in clinical trials studying Polycythemia Vera

Clinical Trials on Polycythemia Vera

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations